Dancann Pharma A/S NORDIC GROWTH MARKET

Equities

DANCAN

DK0061410487

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 2025-02-24			5-day change	1st Jan Change
0.1091 ^DKK	-93.94%		-94.55%	-94.55%

Nov. 18	Dancann Pharma Shares Moved to Spotlight's Observation List	FW
Nov. 17	Stenocare Buys DanCann Pharma's CannGros in Share Exchange Deal	MT

Trading in Dancann Pharma resumes at 15:40

Published on 11/28/2024 at 09:34 am EST - Modified on 11/28/2024 at 09:35 am EST

Finwire - Translated by Marketscreener - See original

Dancann Pharma A/S

-93.94%

Trading in the cannabis company Dancann Pharma will resume at 15:40, according to a press release from Spotlight.

Opening proceedings begin at 15:30, followed by continuous trading from 15:40.

The share has been halted twice during the day.

Latest news about Dancann Pharma A/S

Nov. 18	Dancann Pharma Shares Moved to Spotlight's Observation List	FW
Nov. 17	Stenocare Buys DanCann Pharma's CannGros in Share Exchange Deal	MT
Nov. 17	Dancann Pharma divests CannGros to Stenocare through share transaction	FW
Nov. 16	Stenocare A/S acquired CannGros ApS from DanCann Pharma A/S for DKK 11.4 million.	CI
Nov. 09	5,747,023 Shares of Dancann Pharma A/S are subject to a Lock-Up Agreement Ending on 10-NOV-2025.	CI
Oct. 28	Dancann Pharma Reports Minor Changes in Results - Continued Interest in Production Facility	FW
Oct. 27	DanCann Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Oct. 07	Dancann Pharma Announces CEO Change and Plans for Voluntary Delisting	FW
Oct. 06	DanCann Pharma Board Plans Spotlight Stock Market Delisting	MT
Aug. 26	Dancann Pharma Increases Losses Amid Ongoing Pressure on Price and Volume	FW
Aug. 25	DanCann Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
Jul. 10	Dancann Pharma Sells Production Facility and Secures Bridge Financing	FW
Jul. 09	An undisclosed buyer entered into a conditional sales agreement to acquire Production facility, Biotech Pharm1 of DanCann Pharma A/S from DanCann Pharma A/S for DKK 9.32 million.	CI
Jul. 09	DanCann Pharma Signs Conditional Deal to Sell Danish Facility	MT
May. 23	DanCann Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
May. 19	Dancann Pharma receives regulatory approval for two new cannabis products	FW
May. 19	Dancann Pharma A/S Receives Regulatory Approval for Bedrolite and Bedrobinol from the Danish Medicines Agency Under the Danish Pilot Programme	CI
Apr. 04	DanCann Pharma A/S Provides Financial Guidance for 2025	CI
Apr. 03	DanCann Pharma A/S Auditor Raises 'Going Concern' Doubt	CI
Mar. 13	Dancann Pharma enters partnership with Tetra Pharm Technologies	FW
Mar. 13	DanCann Pharma A/S Forges Cutting Edge Alliance with Tetra Pharm Technologies ApS	CI
Feb. 16	DanCann Pharma A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	CI
Nov. 22	DanCann Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-14	DanCann Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-06-01	DanCann Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Chart Dancann Pharma A/S

Duration

Period

DANCAN: Dynamic Chart

Company Profile

Dancann Pharma A/S is a Denmark-based pharmaceutical biotechnology company powered by cannabinoids. The Company is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma manufactures and distributes prescription drugs (Rx drugs) and over-the-counter drugs (OTCs), mainly focused on pain patients with alternative needs.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 03 - Q4 2025 Earnings Release (Projected)

More about the company